Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $122.08.
Several equities analysts have commented on AXSM shares. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Axsome Therapeutics in a research report on Thursday, June 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Morgan Stanley raised Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $90.00 to $115.00 in a report on Monday, April 29th. Mizuho reissued a “buy” rating and issued a $106.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, June 12th. Finally, Citigroup reduced their price target on shares of Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th.
Read Our Latest Research Report on AXSM
Insider Activity at Axsome Therapeutics
Hedge Funds Weigh In On Axsome Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Washington Trust Advisors Inc. acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $26,000. EntryPoint Capital LLC bought a new position in Axsome Therapeutics in the 1st quarter valued at about $35,000. Russell Investments Group Ltd. boosted its stake in Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares during the last quarter. Covestor Ltd increased its holdings in Axsome Therapeutics by 54,750.0% during the 1st quarter. Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after purchasing an additional 1,095 shares in the last quarter. Finally, Janiczek Wealth Management LLC purchased a new stake in shares of Axsome Therapeutics in the first quarter worth approximately $97,000. 81.49% of the stock is currently owned by institutional investors.
Axsome Therapeutics Stock Up 0.7 %
Shares of NASDAQ:AXSM opened at $81.03 on Friday. The company has a market cap of $3.85 billion, a PE ratio of -12.70 and a beta of 1.26. The firm has a 50 day simple moving average of $75.18 and a 200 day simple moving average of $78.82. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.09 and a current ratio of 3.20. Axsome Therapeutics has a 52 week low of $55.02 and a 52 week high of $98.40.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.11. Axsome Therapeutics had a negative net margin of 118.07% and a negative return on equity of 87.17%. The business had revenue of $75.00 million for the quarter, compared to analysts’ expectations of $69.91 million. As a group, research analysts expect that Axsome Therapeutics will post -4.7 earnings per share for the current year.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
- Five stocks we like better than Axsome Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- The How and Why of Investing in Gold Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is MarketRankā¢? How to Use it
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.